Abstract
Background: When considering the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, or metformin, it is important to understand their weight loss effect as well as the degree of muscle loss caused by each drug in clinical practice.
Objective: To comparatively examine the effects of GLP-1RAs and oral antidiabetic drugs, including SGLT2 inhibitors and metformin, on muscle mass and body weight in patients with type 2 diabetes via a network meta-analysis of randomized controlled trials.
Methods: We included randomized controlled trials evaluating the effects of antidiabetic drugs on muscle mass and body weight. Mean difference (MD) and 95% confidence intervals (CIs) were calculated using a random-effects network meta-analysis.
Results: Of the studies identified, 18 randomized controlled trials (1, 363 subjects) satisfied the eligibility criteria. In all studies, the effects of these drugs on fat-free mass (FFM) were evaluated. Therefore, FFM, which is used as an alternative index of muscle mass, was included in the study. Semaglutide (MD: -1.68, 95% CI: -2.84 to -0.52), dapagliflozin (-0.53, -0.93 to -0.13), and canagliflozin (-0.90, -1.73 to -0.07) showed a significant decrease in FFM compared with the placebo. Metformin did not show a significant decrease in FFM compared with the placebo. When compared with the placebo, semaglutide, dapagliflozin, ipragliflozin, and canagliflozin showed a significant weight loss.
Conclusion: Although semaglutide, dapaglifrozin, and canagliflozin have a large weight loss effect, it is important to pay attention to muscle loss because a decrease in FFM was observed.
Keywords: Antidiabetic drugs, body weight, glucagon-like peptide-1 receptor agonists, muscle mass, network meta-analysis, type 2 diabetes mellitus.
[1]
Mesinovic J, Zengin A, De Courten B, Ebeling PR, Scott D. Sarcopenia and type 2 diabetes mellitus: A bidirectional relationship. Diabetes Metab Syndr Obes 2019; 12: 1057-72.
[http://dx.doi.org/10.2147/DMSO.S186600 ] [PMID: 31372016]
[http://dx.doi.org/10.2147/DMSO.S186600 ] [PMID: 31372016]
[2]
Roubenoff R. Catabolism of aging: Is it an inflammatory process? Curr Opin Clin Nutr Metab Care 2003; 6(3): 295-9.
[http://dx.doi.org/10.1097/01.mco.0000068965.34812.62 ] [PMID: 12690262]
[http://dx.doi.org/10.1097/01.mco.0000068965.34812.62 ] [PMID: 12690262]
[3]
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. European working group on sarcopenia in older people. Sarcopenia: european consensus on definition and diagnosis: Report of the european working group on sarcopenia in older people. Age Ageing 2010; 39(4): 412-23.
[http://dx.doi.org/10.1093/ageing/afq034 ] [PMID: 20392703]
[http://dx.doi.org/10.1093/ageing/afq034 ] [PMID: 20392703]
[4]
Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 2015; 14(1): 58-74.
[http://dx.doi.org/10.1038/nrd4467 ] [PMID: 25549588]
[http://dx.doi.org/10.1038/nrd4467 ] [PMID: 25549588]
[5]
McLeod M, Breen L, Hamilton DL, Philp A. Live strong and prosper: The importance of skeletal muscle strength for healthy ageing. Biogerontology 2016; 17(3): 497-510.
[http://dx.doi.org/10.1007/s10522-015-9631-7 ] [PMID: 26791164]
[http://dx.doi.org/10.1007/s10522-015-9631-7 ] [PMID: 26791164]
[6]
Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391(10120): 541-51.
[http://dx.doi.org/10.1016/S0140-6736(17)33102-1 ] [PMID: 29221645]
[http://dx.doi.org/10.1016/S0140-6736(17)33102-1 ] [PMID: 29221645]
[7]
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311(22): 2297-304.
[http://dx.doi.org/10.1001/jama.2014.5988 ] [PMID: 24915261]
[http://dx.doi.org/10.1001/jama.2014.5988 ] [PMID: 24915261]
[8]
Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23(4): 591-601.
[http://dx.doi.org/10.1016/j.cmet.2016.02.005 ] [PMID: 26916363]
[http://dx.doi.org/10.1016/j.cmet.2016.02.005 ] [PMID: 26916363]
[9]
Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364(13): 1218-29.
[http://dx.doi.org/10.1056/NEJMoa1008234 ] [PMID: 21449785]
[http://dx.doi.org/10.1056/NEJMoa1008234 ] [PMID: 21449785]
[10]
Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr 2017; 8(3): 511-9.
[http://dx.doi.org/10.3945/an.116.014506 ] [PMID: 28507015]
[http://dx.doi.org/10.3945/an.116.014506 ] [PMID: 28507015]
[11]
Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. Endocrinol Metab (Seoul) 2019; 34(3): 247-62.
[http://dx.doi.org/10.3803/EnM.2019.34.3.247 ] [PMID: 31565876]
[http://dx.doi.org/10.3803/EnM.2019.34.3.247 ] [PMID: 31565876]
[12]
Solymár M, Ivic I, Pótó L, et al. Metformin induces significant reduction of body weight, total cholesterol and LDL levels in the elderly - A meta-analysis. PLoS One 2018; 13(11)e0207947
[http://dx.doi.org/10.1371/journal.pone.0207947 ] [PMID: 30475888]
[http://dx.doi.org/10.1371/journal.pone.0207947 ] [PMID: 30475888]
[13]
McCrimmon RJ, Catarig AM, Frias JP, et al. Effects of once-weekly semaglutide vs. once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia 2020; 63(3): 473-85.
[http://dx.doi.org/10.1007/s00125-019-05065-8 ] [PMID: 31897524]
[http://dx.doi.org/10.1007/s00125-019-05065-8 ] [PMID: 31897524]
[14]
Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97(3): 1020-31.
[http://dx.doi.org/10.1210/jc.2011-2260 ] [PMID: 22238392]
[http://dx.doi.org/10.1210/jc.2011-2260 ] [PMID: 22238392]
[15]
Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ 2005; 331(7521): 897-900.
[http://dx.doi.org/10.1136/bmj.331.7521.897 ] [PMID: 16223826]
[http://dx.doi.org/10.1136/bmj.331.7521.897 ] [PMID: 16223826]
[16]
Buckinx F, Landi F, Cesari M, et al. Pitfalls in the measurement of muscle mass: A need for a reference standard. J Cachexia Sarcopenia Muscle 2018; 9(2): 269-78.
[http://dx.doi.org/10.1002/jcsm.12268 ] [PMID: 29349935]
[http://dx.doi.org/10.1002/jcsm.12268 ] [PMID: 29349935]
[17]
Higgins JP, Altman DG, Gøtzsche PC, et al. Cochrane bias methods group; Cochrane statistical methods group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
[http://dx.doi.org/10.1136/bmj.d5928 ] [PMID: 22008217]
[http://dx.doi.org/10.1136/bmj.d5928 ] [PMID: 22008217]
[18]
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996; 313(7066): 1200.
[http://dx.doi.org/10.1136/bmj.313.7066.1200 ] [PMID: 8916759]
[http://dx.doi.org/10.1136/bmj.313.7066.1200 ] [PMID: 8916759]
[19]
Higgins JPT, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration. Chichester, UK John Wiley & Sons 2011.
[20]
Mavridis D, Salanti G. A practical introduction to multivariate meta-analysis. Stat Methods Med Res 2013; 22(2): 133-58.
[http://dx.doi.org/10.1177/0962280211432219 ] [PMID: 22275379]
[http://dx.doi.org/10.1177/0962280211432219 ] [PMID: 22275379]
[21]
Jackson D, White IR, Riley RD. A matrix-based method of moments for fitting the multivariate random effects model for meta-analysis and meta-regression. Biom J 2013; 55(2): 231-45.
[http://dx.doi.org/10.1002/bimj.201200152 ] [PMID: 23401213]
[http://dx.doi.org/10.1002/bimj.201200152 ] [PMID: 23401213]
[22]
Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PLoS One 2013; 8(10)e76654
[http://dx.doi.org/10.1371/journal.pone.0076654 ] [PMID: 24098547]
[http://dx.doi.org/10.1371/journal.pone.0076654 ] [PMID: 24098547]
[23]
Jackson D, Boddington P, White IR. The design-by-treatment interaction model: a unifying framework for modelling loop inconsistency in network meta-analysis. Res Synth Methods 2016; 7(3): 329-32.
[http://dx.doi.org/10.1002/jrsm.1188 ] [PMID: 26588593]
[http://dx.doi.org/10.1002/jrsm.1188 ] [PMID: 26588593]
[24]
Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001; 44(12): 2210-9.
[http://dx.doi.org/10.1007/s001250100031 ] [PMID: 11793023]
[http://dx.doi.org/10.1007/s001250100031 ] [PMID: 11793023]
[25]
Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10(10): 1008-15.
[http://dx.doi.org/10.1038/oby.2002.137 ] [PMID: 12376581]
[http://dx.doi.org/10.1038/oby.2002.137 ] [PMID: 12376581]
[26]
Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care 2004; 27(8): 1915-21.
[http://dx.doi.org/10.2337/diacare.27.8.1915 ] [PMID: 15277417]
[http://dx.doi.org/10.2337/diacare.27.8.1915 ] [PMID: 15277417]
[27]
Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA. Effect of pioglitazone on body composition and energy expenditure: A randomized controlled trial. Metabolism 2005; 54(1): 24-32.
[http://dx.doi.org/10.1016/j.metabol.2004.07.008 ] [PMID: 15562376]
[http://dx.doi.org/10.1016/j.metabol.2004.07.008 ] [PMID: 15562376]
[28]
Gastaldelli A, Miyazaki Y, Pettiti M, et al. The effect of rosiglitazone on the liver: Decreased gluconeogenesis in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91(3): 806-12.
[http://dx.doi.org/10.1210/jc.2005-1159 ] [PMID: 16352689]
[http://dx.doi.org/10.1210/jc.2005-1159 ] [PMID: 16352689]
[29]
Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007; 82(3): 275-81.
[http://dx.doi.org/10.1038/sj.clpt.6100146 ] [PMID: 17361126]
[http://dx.doi.org/10.1038/sj.clpt.6100146 ] [PMID: 17361126]
[30]
Shah PK, Mudaliar S, Chang AR, et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13(6): 505-10.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01370.x ] [PMID: 21272186]
[http://dx.doi.org/10.1111/j.1463-1326.2011.01370.x ] [PMID: 21272186]
[31]
Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp 2013; 75: 88-92.
[http://dx.doi.org/10.1016/j.curtheres.2013.10.002 ] [PMID: 24465050]
[http://dx.doi.org/10.1016/j.curtheres.2013.10.002 ] [PMID: 24465050]
[32]
Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382(9896): 941-50.
[http://dx.doi.org/10.1016/S0140-6736(13)60683-2 ] [PMID: 23850055]
[http://dx.doi.org/10.1016/S0140-6736(13)60683-2 ] [PMID: 23850055]
[33]
Blonde L, Stenlöf K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 2016; 128(4): 371-80.
[http://dx.doi.org/10.1080/00325481.2016.1169894 ] [PMID: 27002421]
[http://dx.doi.org/10.1080/00325481.2016.1169894 ] [PMID: 27002421]
[34]
Fadini GP, Bonora BM, Zatti G, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: A randomized placebo-controlled trial. Cardiovasc Diabetol 2017; Apr; 416(1): 42 017-0529-3..
[http://dx.doi.org/10.1186/s12933-017-0529-3]
[http://dx.doi.org/10.1186/s12933-017-0529-3]
[35]
Shimizu M, Suzuki K, Kato K, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab 2019; 21(2): 285-92.
[http://dx.doi.org/10.1111/dom.13520 ] [PMID: 30178600]
[http://dx.doi.org/10.1111/dom.13520 ] [PMID: 30178600]
[36]
Yamakage H, Tanaka M, Inoue T, Odori S, Kusakabe T, Satoh-Asahara N. Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial. J Diabetes Investig 2020; 11(3): 653-61.
[http://dx.doi.org/10.1111/jdi.13179 ] [PMID: 31721467]
[http://dx.doi.org/10.1111/jdi.13179 ] [PMID: 31721467]
[37]
Inoue H, Morino K, Ugi S, et al. SUMS-ADDIT-1 Research group. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial. J Diabetes Investig 2019; 10(4): 1012-21.
[PMID: 30536746]
[PMID: 30536746]
[38]
Feng WH, Bi Y, Li P, et al. Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial. J Diabetes Investig 2019; 10(2): 399-407.
[http://dx.doi.org/10.1111/jdi.12888 ] [PMID: 29957886]
[http://dx.doi.org/10.1111/jdi.12888 ] [PMID: 29957886]
[39]
Takeshita Y, Kita Y, Kato KI, et al. Effects of metformin and alogliptin on body composition in people with type 2 diabetes. J Diabetes Investig 2019; 10(3): 723-30.
[http://dx.doi.org/10.1111/jdi.12920 ] [PMID: 30156056]
[http://dx.doi.org/10.1111/jdi.12920 ] [PMID: 30156056]
[40]
Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol 2019; 7(11): 834-44.
[http://dx.doi.org/10.1016/S2213-8587(19)30311-0 ] [PMID: 31540867]
[http://dx.doi.org/10.1016/S2213-8587(19)30311-0 ] [PMID: 31540867]
[41]
Szulc P, Munoz F, Marchand F, Chapurlat R, Delmas PD. Rapid loss of appendicular skeletal muscle mass is associated with higher all-cause mortality in older men: The prospective MINOS study. Am J Clin Nutr 2010; 91(5): 1227-36.
[http://dx.doi.org/10.3945/ajcn.2009.28256 ] [PMID: 20237137]
[http://dx.doi.org/10.3945/ajcn.2009.28256 ] [PMID: 20237137]
[42]
Marso SP, Bain SC, Consoli A, et al. SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834-44.
[http://dx.doi.org/10.1056/NEJMoa1607141 ] [PMID: 27633186]
[http://dx.doi.org/10.1056/NEJMoa1607141 ] [PMID: 27633186]
[43]
Abdulla H, Phillips B, Smith K, Wilkinson D, Atherton PJ, Idris I. Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Curr Diabetes Rev 2014; 10(5): 327-35.
[http://dx.doi.org/10.2174/1573399810666141017153749 ] [PMID: 25323297]
[http://dx.doi.org/10.2174/1573399810666141017153749 ] [PMID: 25323297]
[44]
Dimitriadis G, Mitrou P, Lambadiari V, Maratou E, Raptis SA. Insulin effects in muscle and adipose tissue. Diabetes Res Clin Pract 2011; 93(Suppl. 1): S52-9.
[http://dx.doi.org/10.1016/S0168-8227(11)70014-6 ] [PMID: 21864752]
[http://dx.doi.org/10.1016/S0168-8227(11)70014-6 ] [PMID: 21864752]
[45]
Nagai Y, Fukuda H, Kawanabe S, Nakagawa T, Ohta A, Tanaka Y. Differing effect of the sodium-glucose cotransporter 2 inhibitor ipragliflozin on the decrease of fat mass vs. lean mass in patients with or without metformin therapy. J Clin Med Res 2019; 11(4): 297-300.
[http://dx.doi.org/10.14740/jocmr3785 ] [PMID: 30937121]
[http://dx.doi.org/10.14740/jocmr3785 ] [PMID: 30937121]
[46]
Lee CG, Boyko EJ, Barrett-Connor E, et al. Osteoporotic fractures in men (mros) study research group. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care 2011; 34(11): 2381-6.
[http://dx.doi.org/10.2337/dc11-1032 ] [PMID: 21926282]
[http://dx.doi.org/10.2337/dc11-1032 ] [PMID: 21926282]
[47]
Hasan MM, Shalaby SM, El-Gendy J, Abdelghany EMA. Beneficial effects of metformin on muscle atrophy induced by obesity in rats. J Cell Biochem 2019; 120(4): 5677-86.
[http://dx.doi.org/10.1002/jcb.27852 ] [PMID: 30320911]
[http://dx.doi.org/10.1002/jcb.27852 ] [PMID: 30320911]
[48]
Tsurutani Y, Nakai K, Inoue K, et al. Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study. Diabetes Obes Metab 2018; 20(11): 2675-9.
[http://dx.doi.org/10.1111/dom.13421 ] [PMID: 29893003]
[http://dx.doi.org/10.1111/dom.13421 ] [PMID: 29893003]
[49]
Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002; 50(5): 889-96.
[http://dx.doi.org/10.1046/j.1532-5415.2002.50216.x ] [PMID: 12028177]
[http://dx.doi.org/10.1046/j.1532-5415.2002.50216.x ] [PMID: 12028177]
Article Metrics
122
1